Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 18Recruiting 11Withdrawn 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1Colonic Polyps 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Eflornithine × Clear all
NCT01245816 2015-04-24

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Withdrawn
Gastrointestinal

Colonic Polyps, Adenomatous Polyposis Coli

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡